

## Flumazenil

<b>CAUTION: High Administration Risk Rating</b>	
<b>Form</b>	500 microgram (0.5mg) per 5mL ampoule
<b>Reconstitution</b>	Already in solution
<b>Compatibility &amp; Stability</b>	Sodium Chloride 0.9% Glucose 5%
<b>Administration</b>	<p><b><u>IV Injection</u></b> Administer slowly over 15 seconds into a large vein.</p> <p><b><u>Continuous IV Infusion</u></b> Dilute 2.5mg flumazenil (5 x 5mL ampoules) to 50mL with compatible infusion fluid in a 50mL syringe (50 microgram/mL solution). Administer at a rate of 100 - 400 micrograms per hour depending on response. Stop infusion every 6 hours to check whether re-sedation occurs. Preferably administer via a central venous access device to avoid potential venous irritation. If given peripherally, choose a large vein and monitor the injection site closely.</p>
<b>Extravasation</b>	Extravasation is likely to cause tissue damage because of extreme pH (less than 5).
<b>Additional Information</b>	<ul style="list-style-type: none"> <li>Flumazenil should only be administered by, or under the direct supervision of, personnel experienced in its use.</li> <li>Half-life is very short (40-80 minutes), therefore an infusion may be necessary if drowsiness returns after a single dose.</li> </ul>

**Information provided relates to Anexate® manufactured by Cheplapharm Arzneimittel GmbH.**